GeneticsTier 1Medical Sciences concept

Gene therapy principles and inheritance pattern implications

Core concept

Gene therapy replaces/supplements a defective gene product -- applicability differs fundamentally by inheritance pattern, and this is the tested concept
Autosomal recessive / X-linked recessive (loss-of-function) disease: adding a single functional copy of the gene is often sufficient to restore adequate protein function -- these conditions are the most amenable to straightforward gene-addition therapy
Autosomal dominant disease caused by a gain-of-function or dominant-negative mutation: simply adding a normal gene copy does not help, because the mutant allele's product continues to interfere -- these need gene silencing/editing (targeting the mutant allele itself), not gene addition

Approved/established gene-addition successes are almost all recessive conditions: SMA (biallelic SMN1 loss), certain inherited retinal dystrophies (biallelic RPE65 mutations), some haemophilias (X-linked recessive, factor deficiency)
For dominant-negative disorders (e.g. some forms of osteogenesis imperfecta, some cardiomyopathies), strategies must specifically knock down or correct the mutant allele (e.g. allele-specific silencing, gene editing) -- gene addition alone leaves the toxic mutant product unopposed
Haploinsufficiency-based dominant disease (loss of one copy is itself insufficient, no toxic gain-of-function) is actually more analogous to recessive disease for therapy purposes -- adding back a functional copy can restore adequate total gene dosage

Trap: assuming any single-gene disorder is equally suited to gene-addition therapy -- the underlying molecular mechanism (loss-of-function vs dominant-negative/gain-of-function) determines whether addition alone can work
When a vignette describes a dominant condition where a mutant protein actively disrupts normal protein function (dominant-negative), the correct answer for a gene therapy strategy is one that removes/silences the mutant allele, not one that simply supplies a wild-type copy
Delivery vector and target tissue accessibility are separate practical constraints (e.g. CNS conditions limited by blood-brain barrier, muscle disease requiring widespread systemic delivery) that further limit which conditions are currently treatable regardless of inheritance pattern

Same loss-of-function vs dominant-negative distinction underlies why some AD conditions show variable severity depending on which specific mutation is present (missense dominant-negative vs a null allele causing haploinsufficiency)
Links to variant pathogenicity assessment -- correctly classifying the functional consequence of a variant is a prerequisite for choosing the right therapeutic strategy
CRISPR/gene-editing approaches (as opposed to gene addition) are increasingly used specifically to address dominant-negative and gain-of-function disease where addition-only strategies fail

3 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.